Helsinn Group, a fully integrated, global biopharma company with a track record of over forty years of commercial execution and a strong focus in oncology and rare diseases, has closed a financing agreement with Oberland
Helsinn Group, a fully integrated, global biopharma company with a track record of over forty years of commercial execution and a strong focus in oncology and rare diseases, has closed a financing agreement with Oberland